20
Divis Laboratories Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is NAPROXEN USP, with a corresponding US DMF Number 13866.
Remarkably, this DMF maintains an Active status since its submission on November 27, 1998, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of July 24, 2015, and payment made on July 17, 2015, indicating their dedication to facilitating drug approvals, Categorized as Type II